Arch Biopartners Inc. Opens the Market

TORONTO, March 30, 2015 /CNW/ - Richard Muruve, CEO and Director, Arch Biopartners Inc. (ACH)  joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange.  Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for medical needs. The Company's portfolio includes MetaMxTM which targets brain tumor initiating cells. Arch Biopartners is developing new treatments for Pseudomonas aeruginosa respiratory infections, inflammation based diseases, sepsis and cancer metastasis. Arch Biopartners Inc. commenced trading on TSX Venture Exchange on February 23, 2015.

SOURCE Toronto Stock Exchange

Image with caption: "Richard Muruve, CEO and Director, Arch Biopartners Inc. (ACH) joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange. Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for medical needs. The Company’s portfolio includes MetaMx(TM) which targets brain tumor initiating cells. Arch Biopartners is developing new treatments for Pseudomonas aeruginosa respiratory infections, inflammation based diseases, sepsis and cancer metastasis. Arch Biopartners Inc. commenced trading on TSX Venture Exchange on February 23, 2015. (CNW Group/Toronto Stock Exchange)". Image available at: http://photos.newswire.ca/images/download/20150330_C7807_PHOTO_EN_13699.jpg

For further information: please visit www.archbiopartners.com.

RELATED LINKS
http://www.tse.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890